C12Y 105/01
Oxidoreductases acting on the ch-nh group of donors: with nad+ or nadp+
Official title: with NAD+ or NADP+ as acceptor (1.5.1)
C12Y105/01 (Oxidoreductases acting on the ch-nh group of donors: with nad+ or nadp+) appears on 139 US grants and 247 published applications in this corpus.
Search patents in C12Y- Granted patents
- 139
- Published applications
- 247
- Assignees
- 134
- Inventors
- 585
- Latest grant
- 4 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1992 | 1 | 0 |
| 1993 | 0 | 0 |
| 1994 | 0 | 0 |
| 1995 | 2 | 0 |
| 1996 | 0 | 0 |
| 1997 | 0 | 0 |
| 1998 | 1 | 0 |
| 1999 | 0 | 0 |
| 2000 | 1 | 0 |
| 2001 | 1 | 1 |
| 2002 | 1 | 2 |
| 2003 | 2 | 3 |
| 2004 | 1 | 2 |
| 2005 | 0 | 3 |
| 2006 | 2 | 3 |
| 2007 | 1 | 2 |
| 2008 | 2 | 2 |
| 2009 | 0 | 2 |
| 2010 | 1 | 3 |
| 2011 | 2 | 3 |
| 2012 | 0 | 4 |
| 2013 | 1 | 4 |
| 2014 | 1 | 7 |
| 2015 | 5 | 14 |
| 2016 | 5 | 10 |
| 2017 | 9 | 10 |
| 2018 | 15 | 14 |
| 2019 | 9 | 24 |
| 2020 | 9 | 20 |
| 2021 | 11 | 20 |
| 2022 | 12 | 18 |
| 2023 | 9 | 18 |
| 2024 | 8 | 18 |
| 2025 | 16 | 21 |
| 2026 | 11 | 19 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
- C12Y 105/01003Dihydrofolate reductase53
- C12Y 105/01028Opine dehydrogenase20
- C12Y 105/0102Methylenetetrahydrofolate reductase [nadh]19
- C12Y 105/01023Tauropine dehydrogenase16
- C12Y 105/01024N5-ornithine synthase16
- C12Y 105/01002Pyrroline-5-carboxylate reductase7
- C12Y 105/0103Flavin reductase7
- C12Y 105/01005Methylenetetrahydrofolate dehydrogenase5
All 41 subgroupsShow fewer
- C12Y 105/010271,2-dehydroreticulinium reductase5
- C12Y 105/01015Methylenetetrahydrofolate dehydrogenase4
- C12Y 105/010346,7-dihydropteridine reductase4
- C12Y 105/01036Flavin reductase4
- C12Y 105/01001Pyrroline-2-carboxylate reductase3
- C12Y 105/01021Delta1-piperideine-2-carboxylate reductase2
- C12Y 105/01038Fmn reductase2
- C12Y 105/01041Riboflavin reductase2
- C12Y 105/01006Formyltetrahydrofolate dehydrogenase1
- C12Y 105/01011D-octopine dehydrogenase1
- C12Y 105/01017Alanopine dehydrogenase1
- C12Y 105/01019D-nopaline dehydrogenase , i.e. d-nopaline synthase1
- C12Y 105/01029Fmn reductase1
- C12Y 105/01043Carboxynorspermidine synthase1
- C12Y 105/01007Saccharopine dehydrogenase0
- C12Y 105/01008Saccharopine dehydrogenase0
- C12Y 105/01009Saccharopine dehydrogenase0
- C12Y 105/0101Saccharopine dehydrogenase0
- C12Y 105/010121-pyrroline-5-carboxylate dehydrogenase0
- C12Y 105/01016D-lysopine dehydrogenase0
- C12Y 105/01018Ephedrine dehydrogenase0
- C12Y 105/01022Strombine dehydrogenase0
- C12Y 105/01025Thiomorpholine-carboxylate dehydrogenase0
- C12Y 105/01026Beta-alanopine dehydrogenase0
- C12Y 105/01031Berberine reductase0
- C12Y 105/01032Vomilenine reductase0
- C12Y 105/01033Pteridine reductase0
- C12Y 105/01037Fad reductase0
- C12Y 105/01039Fmn reductase0
- C12Y 105/01048-hydroxy-5-deazaflavin:nadph oxidoreductase0
- C12Y 105/01042Fmn reductase0
- C12Y 105/01044Festuclavine dehydrogenase0
- C12Y 105/01045Fad reductase [nadh]0
Recent patents
- Small molecules for dual function positron emission tomography (PET) and cell suicide switches4 Aug 2026US 12,697,403 B2The Trustees of the University of Pennsylvania
- Biosynthesis of eriodictyol30 Jun 2026US 12,668,804 B2Conagen Inc.
- Microorganisms and methods for enhancing the availability of reducing equivalents in the presence of methanol, and for producing 1,4-butanediol related thereto30 Jun 2026US 12,668,820 B2Genomatica, Inc.
- Detection of environmental influences by bioluminescence2 Jun 2026US 12,644,104 B2Rheinisch-Westfälische Technische Hochschule (RWTH) Aachen
- IL-13 receptor alpha 2 targeted, zetakine directed T cell immunotherapy21 Apr 2026US 12,606,603 B2Seattle Children's Hospital
- Analytical device for real time luminescence during temperature hold and ramp as used in real time cellular thermal shift assay1 Oct 2026US 2026/0297593 A1The United States of America, as represented by the Secretary, Department of Health and Human Serv
- Inducible programmed cell death-1 (pd1)-cytokine chimera for potentiated immune cell function24 Sep 2026US 2026/0284108 A1Seattle Children's Hospital d/b/a Seattle Children's Research Institute
- Production cell lines with targeted integration sites17 Sep 2026US 2026/0275373 A1Seagen Inc.
- Peptide expression constructs and uses thereof20 Aug 2026US 2026/0242414 A1Kyoto Prefectural Public University Corporation
- Modulation of genes coding for lysine ketoglutarate reductase20 Aug 2026US 2026/0242812 A1Philip Morris Products S. A.
Most cited
By later US patents
- Methods of generating desired amino-terminal residues in proteins51US 5,093,242 AMassachusetts Institute of Technology · 1992
- Treatment using herpes simplex virus34US 7,897,146 B2Crusade Laboratories Limited · 2011
- Combination therapy with an anti-hyaluronan agent and therapeutic agent23US 9,913,822 B2Halozyme, Inc. · 2018
- Protein enriched microvesicles and methods of making and using the same19US 9,593,356 B2Takara Bio USA, Inc. · 2017
- Engineered imine reductases and methods for the reductive animation of ketone and amine compounds16US 9,193,957 B2Codexis, Inc. · 2015